Our firm’s Mass Torts Section is handling cases involving Pfizer’s statin medication Lipitor. The complaints allege that the manufacturer failed to warn about the risk of diabetes after several signals of the risk were known in the clinical trials. Statins are meant to reduce the risk of cardiovascular events. Ironically, one group of patients at a much higher risk of cardiovascular events is diabetics. All statin labels now say that a blood glucose measure called Hb1AC may be affected while on the drug. So there is still no warning about diabetes.
The American College of Cardiology (ACC) and the American Heart Association (AHA) released new treatment guidelines in 2013 which have led to some controversy according to Public Citizen, the consumer group in Washington, D.C. A recent study that compared the 2002 guidelines would increase the number of U.S. adults aged 40-75 who are eligible for statin therapy from 43 million to 56 million. This increase would be driven largely by use for primary prevention (in individuals without heart disease), where the evidence for benefit is not well established. Public Citizen’s Health Research Group agrees with the new guidelines when statins are used for secondary prevention. We have seen in the discovery in the Lipitor litigation that the medical literature does not necessarily support healthy females taking Lipitor for primary prevention. Neither does the drug extend the life of a female taking Lipitor for primary prevention. Public Citizen poses the question: why else would an individual be taking a drug every day for the rest of their lives?
Source: Public Citizen
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.